BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 17882282)

  • 1. JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials.
    Pardanani A
    Leukemia; 2008 Jan; 22(1):23-30. PubMed ID: 17882282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.
    Pardanani A; Hood J; Lasho T; Levine RL; Martin MB; Noronha G; Finke C; Mak CC; Mesa R; Zhu H; Soll R; Gilliland DG; Tefferi A
    Leukemia; 2007 Aug; 21(8):1658-68. PubMed ID: 17541402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Janus kinase 2 inhibitors in myeloproliferative disorders.
    Lucia E; Recchia AG; Gentile M; Bossio S; Vigna E; Mazzone C; Madeo A; Morabito L; Gigliotti V; De Stefano L; Caruso N; Servillo P; Franzese S; Bisconte MG; Gentile C; Morabito F
    Expert Opin Investig Drugs; 2011 Jan; 20(1):41-59. PubMed ID: 21128825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disorders.
    Dawson MA; Curry JE; Barber K; Beer PA; Graham B; Lyons JF; Richardson CJ; Scott MA; Smyth T; Squires MS; Thompson NT; Green AR; Wallis NG
    Br J Haematol; 2010 Jul; 150(1):46-57. PubMed ID: 20507304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. JAK2 kinase inhibitors and myeloproliferative disorders.
    Chen AT; Prchal JT
    Curr Opin Hematol; 2010 Mar; 17(2):110-6. PubMed ID: 20087176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. JAK2 mutations and clinical practice in myeloproliferative neoplasms.
    Tefferi A
    Cancer J; 2007; 13(6):366-71. PubMed ID: 18032973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical and clinical activity of ATP mimetic JAK2 inhibitors.
    Wadleigh M; Tefferi A
    Clin Adv Hematol Oncol; 2010 Aug; 8(8):557-63. PubMed ID: 20966892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients.
    Pardanani A; Lasho T; Smith G; Burns CJ; Fantino E; Tefferi A
    Leukemia; 2009 Aug; 23(8):1441-5. PubMed ID: 19295546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. JAK2 inhibitors in the treatment of myeloproliferative neoplasms.
    Tibes R; Bogenberger JM; Geyer HL; Mesa RA
    Expert Opin Investig Drugs; 2012 Dec; 21(12):1755-74. PubMed ID: 22991927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Janus kinase 2 mutations in Philadelphia negative chronic myeloproliferative disorders: clinical implications.
    Panani AD
    Cancer Lett; 2009 Oct; 284(1):7-14. PubMed ID: 19269737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2.
    Purandare AV; McDevitt TM; Wan H; You D; Penhallow B; Han X; Vuppugalla R; Zhang Y; Ruepp SU; Trainor GL; Lombardo L; Pedicord D; Gottardis MM; Ross-Macdonald P; de Silva H; Hosbach J; Emanuel SL; Blat Y; Fitzpatrick E; Taylor TL; McIntyre KW; Michaud E; Mulligan C; Lee FY; Woolfson A; Lasho TL; Pardanani A; Tefferi A; Lorenzi MV
    Leukemia; 2012 Feb; 26(2):280-8. PubMed ID: 22015772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. JAK-mutant myeloproliferative neoplasms.
    Levine RL
    Curr Top Microbiol Immunol; 2012; 355():119-33. PubMed ID: 21823028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of JAK-STAT signaling in the pathogenesis of myeloproliferative disorders.
    Levine RL; Wernig G
    Hematology Am Soc Hematol Educ Program; 2006; ():233-9, 510. PubMed ID: 17124066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy with JAK2 inhibitors for myeloproliferative neoplasms.
    Santos FP; Verstovsek S
    Hematol Oncol Clin North Am; 2012 Oct; 26(5):1083-99. PubMed ID: 23009939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LS104, a non-ATP-competitive small-molecule inhibitor of JAK2, is potently inducing apoptosis in JAK2V617F-positive cells.
    Lipka DB; Hoffmann LS; Heidel F; Markova B; Blum MC; Breitenbuecher F; Kasper S; Kindler T; Levine RL; Huber C; Fischer T
    Mol Cancer Ther; 2008 May; 7(5):1176-84. PubMed ID: 18483305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo characterization of SGI-1252, a small molecule inhibitor of JAK2.
    Ahmed KB; Warner SL; Chen A; Gourley ES; Liu X; Vankayalapati H; Nussenzveig R; Prchal JT; Bearss DJ; Parker CJ
    Exp Hematol; 2011 Jan; 39(1):14-25. PubMed ID: 20934482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The current status and the future of JAK2 inhibitors for the treatment of myeloproliferative diseases.
    Hitoshi Y; Lin N; Payan DG; Markovtsov V
    Int J Hematol; 2010 Mar; 91(2):189-200. PubMed ID: 20191331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Janus kinase inhibitors: an update on the progress and promise of targeted therapy in the myeloproliferative neoplasms.
    Stein BL; Crispino JD; Moliterno AR
    Curr Opin Oncol; 2011 Nov; 23(6):609-16. PubMed ID: 21993415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined inhibition of Janus kinase 1/2 for the treatment of JAK2V617F-driven neoplasms: selective effects on mutant cells and improvements in measures of disease severity.
    Liu PC; Caulder E; Li J; Waeltz P; Margulis A; Wynn R; Becker-Pasha M; Li Y; Crowgey E; Hollis G; Haley P; Sparks RB; Combs AP; Rodgers JD; Burn TC; Vaddi K; Fridman JS
    Clin Cancer Res; 2009 Nov; 15(22):6891-900. PubMed ID: 19887489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms.
    Stivala S; Codilupi T; Brkic S; Baerenwaldt A; Ghosh N; Hao-Shen H; Dirnhofer S; Dettmer MS; Simillion C; Kaufmann BA; Chiu S; Keller M; Kleppe M; Hilpert M; Buser AS; Passweg JR; Radimerski T; Skoda RC; Levine RL; Meyer SC
    J Clin Invest; 2019 Mar; 129(4):1596-1611. PubMed ID: 30730307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.